InterCure Ltd. (NASDAQ:INCR) Sees Large Growth in Short Interest

InterCure Ltd. (NASDAQ:INCR) was the target of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 4,086 shares, an increase of 57.8% from the January 15th total of 2,590 shares. Based on an average trading volume of 46,481 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 46,481 shares, the short-interest ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of InterCure in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

InterCure Trading Up 1.1%

NASDAQ:INCR traded up $0.01 on Monday, hitting $0.90. 48,560 shares of the company’s stock were exchanged, compared to its average volume of 42,493. InterCure has a 52 week low of $0.68 and a 52 week high of $1.77. The firm has a 50-day moving average price of $1.05 and a 200-day moving average price of $1.34. The company has a current ratio of 1.85, a quick ratio of 1.09 and a debt-to-equity ratio of 0.27.

InterCure (NASDAQ:INCR) last released its quarterly earnings results on Wednesday, October 8th. The company reported ($0.02) EPS for the quarter. The business had revenue of $19.25 million during the quarter.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.